Karus Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Karus Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0490
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Karus Therapeutics Ltd (Karus) is a drug development company that designs and develops cancer therapies. The company offers small molecule drugs with immunotherapy for the treatment of hematological and solid tumors. Its pipeline products include KA2507 and KA2237 inhibitors. Karus’ KA2507 is a highly selective inhibitor of HDAC6 for the treatment of multiple myeloma and inflammatory diseases. The company’s KA2237 is a dual selective inhibitor of P13K for the treatment of solid tumors and hematological cancers. Its development programs offer medical needs in the fields of chronic inflammation, retaining drug design, immunotherapeutic modes, haematological malignancies and solid tumours. Karus is headquartered in Oxford, the UK.

Karus Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Karus Therapeutics Raises US$7 Million In First Tranche Of Series B Financing 10
Partnerships 12
Karus Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 12
Babraham Institute And Karus Therapeutics To Explore PI3 Kinase Inhibitors In Treatment of Inflammatory Diseases 13
Karus Therapeutics Ltd – Key Competitors 14
Karus Therapeutics Ltd – Key Employees 15
Karus Therapeutics Ltd – Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Karus Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Karus Therapeutics Raises US$7 Million In First Tranche Of Series B Financing 10
Karus Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 12
Babraham Institute And Karus Therapeutics To Explore PI3 Kinase Inhibitors In Treatment of Inflammatory Diseases 13
Karus Therapeutics Ltd, Key Competitors 14
Karus Therapeutics Ltd, Key Employees 15

List of Figures
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Karus Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Rubicon Research Pvt Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Rubicon Research Pvt Ltd (Rubicon), a subsidiary of Everstone Capital Management, is a drug delivery technology company that develops, manufactures and markets next-generation pharmaceutical products. The company’s products include central nervous system, cardiovascular, cough, cold and anti …
  • First Electric Cooperative Corporation:企業の発電所・SWOT分析2018
    First Electric Cooperative Corporation - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informati …
  • Neurones SA (NRO):企業の財務・戦略的SWOT分析
    Neurones SA (NRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Western Area Power Administration:企業の戦略的SWOT分析
    Western Area Power Administration - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • PTC KAMAZ:企業のM&A・事業提携・投資動向
    PTC KAMAZ - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's PTC KAMAZ Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Dialog Group Bhd (DIALOG):企業の財務・戦略的SWOT分析
    Dialog Group Bhd (DIALOG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Scandinavian Biopharma Holding AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Scandinavian Biopharma Holding AB (Scandinavian) is a biotechnology company that distributes vaccines and immunoglobulin. The company offers diagnostics, vaccines, dental and immunoglobulin products. Its products are used in the therapeutic areas of diphtheria and tetanus, tuberculosis, poli …
  • Crew Energy Inc (CR):企業の財務・戦略的SWOT分析
    Summary Crew Energy Inc (Crew Energy) is an exploration and production company that offers our long-term production and development of crude oil and natural gas resources. The company offers exploration, development, strategic acquisitions, operations, management, and production programs. It operate …
  • Blount International, Inc.:企業の戦略的SWOT分析
    Blount International, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • KBP Instrument Design Bureau:企業の戦略・SWOT・財務分析
    KBP Instrument Design Bureau - Strategy, SWOT and Corporate Finance Report Summary KBP Instrument Design Bureau - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Mitsui O.S.K. Lines, Ltd.:企業の戦略・SWOT・財務分析
    Mitsui O.S.K. Lines, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mitsui O.S.K. Lines, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Shield Therapeutics Plc (STX):企業の財務・戦略的SWOT分析
    Summary Shield Therapeutics Plc (Shield Therapeutics) is a specialty pharmaceutical company that focus on the development and commercialization products for the treatment of anaemia associated with renal and gastrointestinal disorders. The company’s product portfolio includes Feraccru, a stable, non …
  • Krka, d. d., Novo mesto:戦略・SWOT・企業財務分析
    Krka, d. d., Novo mesto - Strategy, SWOT and Corporate Finance Report Summary Krka, d. d., Novo mesto - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Britvic Plc:戦略・SWOT・企業財務分析
    Britvic Plc - Strategy, SWOT and Corporate Finance Report Summary Britvic Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • AstraZeneca Plc (AZN):医療機器:M&Aディール及び事業提携情報
    Summary AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and renal and metabolic diseases; and cancer, besides autoimmune, infection a …
  • Premier Gold Mines Limited:企業の戦略・SWOT・財務情報
    Premier Gold Mines Limited - Strategy, SWOT and Corporate Finance Report Summary Premier Gold Mines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Airgas, Inc.:企業のM&A・事業提携・投資動向
    Airgas, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Airgas, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Tokuyama Corporation (4043):企業の財務・戦略的SWOT分析
    Tokuyama Corporation (4043) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Entergy Corporation (ETR):企業の財務・戦略的SWOT分析
    Entergy Corporation (ETR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Dong-A Socio Holdings Co Ltd (000640):製薬・医療:M&Aディール及び事業提携情報
    Summary Dong-A Socio Holdings Co Ltd (Dong-A Socio Holdings), formerly Dong-A Pharmaceutical Co., Ltd., offers business management services. It is a subsidiary of Dong-A Socio Group. It operates in various markets such as pharmaceuticals, food and beverages, logistics, IT, and materials. The group f …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆